Clinical Response definition

Clinical Response means a non-Promotional, scientific communication to address Unsolicited Requests for medical information.
View Source
Clinical Response has become a com- mon means for presenting clinically rele- vant data. In particular, the 2 mm threshold is a level clinicians use to monitor disease progression and evaluate therapeutic suc- cess. Patients’ mean percentage of treat- ment sites with probing reductions ≥2 mm was significantly higher for the SRP plus minocycline microsphere group. In addition to threshold reduction levels, reducing prob- ing depths to less than 5 mm is also impor-
View Source
Clinical Response means a nomPromotional, scientific communication to address Unsolicited Requests for medical information.
View Source

Examples of Clinical Response in a sentence

  • Treatment visit with Clinical Labs Visits during which treatment assessments are performed and for which clinical laboratory specimens are collected as defined in the clinical protocol including visits scheduled for Weeks 4, 13, 25, and 37 Clinical Response Visit Visit in which disease assessments are performed as defined in the clinical protocol including visits scheduled for Weeks 9, 22, 34, and 46.

  • Clinical Response shall be available on all County holidays during the workday, in addition to afterhours coverage.

  • The Site will conduct the study entitled “A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open–Label Vedolizumab Intravenous Therapy” (the “Study”) at Institution in accordance with the protocol, incorporated herein by reference (the 1.

  • Combined results from the two pivotal adalimumab trials, which enrolled a total of 633 patients, showed that approximately 50% of the 316 patients who were treated with adalimumab achieved a response in the Hidradenitis Suppurativa Clinical Response, or HiSCR, while approximately 27% of the 317 patients who received placebo achieved a HiSCR response, in each case at the end of a 12-week treatment period.

  • The Site will conduct the study entitled “A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open–Label Vedolizumab Intravenous Therapy” (the “Study”) at Institution in accordance with the protocol, incorporated herein by reference (the “Protocol”).